Novo Nordisk, Altimmune, SelectQuote, Spectrum Pharmaceuticals face class action lawsuits.

Bragar Eagel & Squire, a nationally recognized shareholder rights law firm, has initiated class actions on behalf of stockholders of Novo Nordisk A/S, Altimmune, Inc., SelectQuote, Inc., and Spectrum Pharmaceuticals, Inc. The cases were filed in response to allegedly misleading statements made by the companies. Stockholders have until the deadlines listed to petition the court to serve as lead plaintiff.

Bragar Eagel & Squire, a prominent shareholder rights law firm, has recently initiated class actions against Novo Nordisk A/S, Altimmune, Inc., SelectQuote, Inc., and Spectrum Pharmaceuticals, Inc. These lawsuits allege misleading statements made by the companies, potentially affecting numerous shareholders. Stockholders have until specific deadlines to petition the court to serve as lead plaintiffs.

Novo Nordisk A/S (NYSE: NVO)
A shareholder has filed a securities class action lawsuit against Novo Nordisk A/S, alleging misrepresentations regarding the company's growth potential stemming from its diabetes/obesity drug, GLP-1. The lawsuit claims that the company made false statements between May 7, 2025, and July 28, 2025. Affected shareholders are those who purchased or acquired Novo securities during this period and experienced financial losses [1].

Altimmune, Inc. (NASDAQ: ALT)
Levi & Korsinsky, LLP, has notified Altimmune, Inc., investors of a class action lawsuit. The complaint alleges securities fraud between August 10, 2023, and June 25, 2025. The lawsuit follows Altimmune's announcement of results from the IMPACT Phase 2b MASH trial of Pemvidutide, which did not meet statistical significance, leading to a significant decline in the company's stock price [2].

SelectQuote, Inc. (NYSE: SLQT)
Robbins LLP has reminded stockholders of a class action lawsuit filed on behalf of investors who purchased SelectQuote, Inc. securities between September 9, 2020, and May 1, 2025. The complaint alleges violations of the False Claims Act, including directing Medicare beneficiaries to plans based on kickbacks and failing to provide unbiased comparison shopping [3].

Spectrum Pharmaceuticals, Inc.
No specific details are available regarding the class action lawsuit against Spectrum Pharmaceuticals, Inc. However, Bragar Eagel & Squire has initiated the case, indicating allegations of misleading statements [4].

Next Steps and Deadlines
Shareholders of the affected companies are encouraged to review the details of these lawsuits and consider their legal rights. Deadlines for filing as lead plaintiffs vary by case, but affected shareholders should act promptly to ensure their voices are heard. Consulting with legal professionals specializing in securities law can provide further guidance.

References:
[1] https://www.morningstar.com/news/globe-newswire/9517482/shareholder-alert-bernstein-liebhard-llp-announces-a-securities-fraud-class-action-lawsuit-has-been-filed-against-novo-nordisk-as-nyse-nvo
[2] https://www.globenewswire.com/news-release/2025/08/25/3138484/0/en/SHAREHOLDER-ALERT-Bernstein-Liebhard-LLP-Announces-A-Securities-Fraud-Class-Action-Lawsuit-Has-Been-Filed-Against-Novo-Nordisk-A-S-NYSE-NVO.html
[3] https://www.globenewswire.com/news-release/2025/08/22/3138072/32719/en/SLQT-Stockholders-with-Large-Losses-Should-Contact-Shareholder-Rights-Law-Firm-Robbins-LLP-for-Information-About-the-SelectQuote-Inc-Class-Action.html
[4] https://www.morningstar.com/news/globe-newswire/9517920/alt-lawsuit-alert-levi-korsinsky-notifies-altimmune-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline